rs139624145
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000527.5(LDLR):c.1444G>A(p.Asp482Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000731 in 1,613,892 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D482G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1444G>A | p.Asp482Asn | missense_variant | 10/18 | ENST00000558518.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.1444G>A | p.Asp482Asn | missense_variant | 10/18 | 1 | NM_000527.5 | P3 |
Frequencies
GnomAD3 genomes ? AF: 0.0000394 AC: 6AN: 152150Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251310Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135854
GnomAD4 exome AF: 0.0000766 AC: 112AN: 1461742Hom.: 0 Cov.: 35 AF XY: 0.0000660 AC XY: 48AN XY: 727178
GnomAD4 genome ? AF: 0.0000394 AC: 6AN: 152150Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:18
Likely pathogenic, criteria provided, single submitter | research | Iberoamerican FH Network | Mar 01, 2016 | - - |
Pathogenic, no assertion criteria provided | research | Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum | - | - - |
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Asp482Asn (sometimes called p.Asp461Asn) variant in LDLR has been reported in at least 24 individuals (including 4 Czech, 3 German, 1 Norwegian, 1 Italian, and 1 Dutch individuals) with Familial Hypercholesterolemia, segregated with disease in 5 affected relatives from 2 families (PMID: 26036859, 22698793, 9026534, 15199436, 11857755, 16159606, 21310417, 11139254, 11810272), and has been identified in 0.008526% (11/129018) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs139624145). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS, a likely pathogenic variant, and a pathogenic variant in ClinVar (Variation ID: 161284). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS4, PP1_Moderate, PP3 (Richards 2015). - |
Likely pathogenic, criteria provided, single submitter | research | Fundacion Hipercolesterolemia Familiar | Mar 01, 2016 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Cardiovascular Genetics Laboratory, PathWest Laboratory Medicine WA - Fiona Stanley Hospital | Jul 22, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 11, 2017 | Across a selection of the available literature, the LDLR c.1444G>A (p.Asp482Asn) variant has been identified in a heterozygous state in 36 cases with familial hypercholesterolemia (Taylor et al. 2010; Martin et al. 2016; Braenne et al. 2016). Control data are unavailable for this variant, which is reported at a frequency of 0.000087 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the evidence, the p.Asp482Asn variant is classified as pathogenic for familial hypercholesterolemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 08, 2024 | This missense variant (also known as p.Asp461Asn in the mature protein) replaces aspartic acid with asparagine at codon 482 in the LDLR type B repeat 2 of the EGF precursor homology domain of the LDLR protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This LDLR variant has been reported in over 40 heterozygous individuals affected with familial hypercholesterolemia (PMID: 8535447, 10559517, 15523646, 16389549, 21310417, 20236128, 23375686, 33740630, 34037665; Color internal data) and is a recurrent variant among Irish individuals affected with familial hypercholesterolemia (PMID: 15523646). This variant has also been observed in compound heterozygous state with a known pathogenic LDLR variant in two individuals affected with severe homozygous familial hypercholesterolemia, a phenotype expected of having two deleterious LDLR variants (PMID: 30270091). It has been shown that this variant segregates with disease in three affected individuals in one family (PMID: 8535447). This variant has been identified in 11/282680 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same codon (p.Asp482Tyr, p.Asp482His and p.Asp482Gly), are considered to be disease-causing (ClinVar variation ID: 251845, 251844 and 251846), suggesting that aspartic acid at this position is important for LDLR protein function. Based on the available evidence, this variant is classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | May 11, 2017 | The c.1444G>A (p.Asp482Asn) variant in the LDLR gene has been reported in patients with hypercholesterolemia [PMID 8535447, 23375686, 20236128, 16159606, 21326404; legacy name 461]. This variant was observed in five heterozygous individuals in the ExAC population database (http://exac.broadinstitute.org/variant/19-11224296-G-A). Aspartate at position 482 of the LDLR protein is conserved in mammals and while not clinically validated, computer-based algorithms (SIFT and Polyphen-2) predict this p.Asp482Asn change to be deleterious. This c.1444G>A (p.Asp482Asn) variant is thus classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille | Mar 30, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Aug 17, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | research | Brunham Lab, Centre for Heart and Lung Innovation, University of British Columbia | May 11, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Robarts Research Institute, Western University | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Oct 16, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation | Nov 05, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 28, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | research | Institute for Integrative and Experimental Genomics, University of Luebeck | - | - - |
Familial hypercholesterolemia Pathogenic:4Other:1
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | Variant interpreted as Pathogenic and reported on 09-10-2018 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 05, 2018 | Variant summary: LDLR c.1444G>A (p.Asp482Asn) results in a conservative amino acid change located in the LDLR class B repeat of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 277372 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in LDLR causing Familial Hypercholesterolemia (4e-05 vs 0.0013), allowing no conclusion about variant significance. c.1444G>A has been reported in the literature in multiple individuals affected with Familial Hypercholesterolemia (Bochmann_2001, Bunn_2002, Fouchier_2001, Graham_1999, Graham_2005, Martin_2016, Ward_1995). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven ClinVar submissions from other clinical diagnostic laboratories (evaluation after 2014) cite the variant as likely pathogenic/pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 22, 2024 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 482 of the LDLR protein (p.Asp482Asn). This variant is present in population databases (rs139624145, gnomAD 0.009%). This missense change has been observed in individuals with hypercholesterolemia (PMID: 8535447, 16389549, 20236128, 21310417, 23375686). This variant is also known as p.Asp461Asn. ClinVar contains an entry for this variant (Variation ID: 161284). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function with a positive predictive value of 95%. This variant disrupts the p.Asp482 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16389549, 20236128, 21310417). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 07, 2023 | This missense variant (also known as p.Asp461Asn in the mature protein) replaces aspartic acid with asparagine at codon 482 in the LDLR type B repeat 2 of the EGF precursor homology domain of the LDLR protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This LDLR variant has been reported in over 40 heterozygous individuals affected with familial hypercholesterolemia (PMID: 8535447, 10559517, 15523646, 16389549, 21310417, 20236128, 23375686, 33740630, 34037665; Color internal data) and is a recurrent variant among Irish individuals affected with familial hypercholesterolemia (PMID: 15523646). This variant has also been observed in compound heterozygous state with a known pathogenic LDLR variant in two individuals affected with severe homozygous familial hypercholesterolemia, a phenotype expected of having two deleterious LDLR variants (PMID: 30270091). It has been shown that this variant segregates with disease in three affected individuals in one family (PMID: 8535447). This variant has been identified in 11/282680 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same codon (p.Asp482Tyr, p.Asp482His and p.Asp482Gly), are considered to be disease-causing (ClinVar variation ID: 251845, 251844 and 251846), suggesting that aspartic acid at this position is important for LDLR protein function. Based on the available evidence, this variant is classified as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Nov 08, 2022 | PP1, PP3, PM2_supporting, PM3, PM5, PS4 - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 29, 2023 | Functional studies showed that D482N, when present in the homozygous or compound heterozygous state, results in decreased LDL receptor activity (Webb et al., 1996); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as D461N; This variant is associated with the following publications: (PMID: 11810272, 18700895, 25487149, 15556094, 20236128, 22883975, 29874871, 34662886, 25637381, 9026534, 8535447, 11857755, 11139254, 15199436, 21310417, 27680772, 15523646, 25682026, 16159606, 22698793, 23375686, 26036859, 27765764, 23680767, 29284604, 24507775, 31447099, 32220565, 35177841, 32719484, 32041611, 33303402, 33740630, 34037665) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Jan 05, 2022 | - - |
Hypercholesterolemia Pathogenic:1Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Dec 03, 2018 | - - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 26, 2023 | The p.D482N variant (also known as c.1444G>A), located in coding exon 10 of the LDLR gene, results from a G to A substitution at nucleotide position 1444. The aspartic acid at codon 482 is replaced by asparagine, an amino acid with highly similar properties. This alteration (also described as legacy p.D461N) has been identified in multiple individuals with familial hypercholesterolemia (FH) (Brænne I et al. Eur. J. Hum. Genet., 2016 Feb;24:191-7; Webb JC et al. J. Lipid Res., 1996 Feb;37:368-81; Ward AJ et al. Hum. Mutat., 1995;6:254-6; Bochmann H et al. Hum. Mutat., 2001;17:76-7; Taylor A et al. Clin. Genet., 2010 Jun;77:572-80; Wang J et al. Arterioscler. Thromb. Vasc. Biol., 2016 12;36:2439-2445; Laurie AD et al. Atheroscler Suppl, 2004 Dec;5:13-5; Ho CK et al. Scott Med J, 2012 Aug;57:148-51; Hooper AJ et al. Atherosclerosis, 2012 Oct;224:430-4). It has been reported to co-segregate with disease in one family (Brænne I et al. Eur J Hum Genet. 2016;24(2):191-7). One study has demonstrated <2% of normal LDL-R activity in an individual with this alteration and a 21 base pair deletion in exon 4 of LDLR (Webb JC et al. J Lipid Res. 1996;37(2):368-81). Another study has reported the p.D482N variant and a second LDLR variant (p.D266E, c.798T>A) in an individual with coronary heart disease (Bochmann H et al. Hum. Mutat., 2001;17:76-7). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at